BRIEF-Silo Pharma Says IND Submission For Intranasal SPC-15 Treatment Expected In 2025
ReutersJan 2, 2025 4:17 PM
Jan 2 (Reuters) - Silo Pharma Inc SILO.O:
SILO PHARMA INC: IND SUBMISSION FOR INTRANASAL SPC-15 TREATMENT EXPECTED IN 2025
Source text: [ID:n0001213900-25-000191]
Further company coverage: SILO.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
U.S. July Nonfarm Payroll Commentary: Short-Term Economic Headwinds May Turn into Mid-Term Bullish Signal for US Stocks
In essence, short-term economic challenges could pave the way for medium-term investment opportunities.TradingKey
4 hours ago
Stablecoins: The Dollar’s Secret Weapon?
You’ve probably heard of USDC. When Circle went public, its stock value popped off. Even Trump made an estimate of a billion dollars on crypto. What exactly is a stablecoin?TradingKey
4 hours ago
Ray Dalio: The Macro Master Behind the All Weather Portfolio
Not many names command as much respect in the investing world as Ray Dalio. He founded Bridgewater Associates, the world’s largest hedge fund, managing over $150 billion at its peak. But... what truly sets Dalio apart isn’t just his success...TradingKey
4 hours ago
SMCI Q4 FY2025 Earnings Preview: Balancing AI Momentum with Margin and Governance Risks
TradingKey - Super Micro Computer, Inc. (NASDAQ: SMCI) is scheduled to report its Q4 FY2025 earnings on Tuesday. The outlook for SMCI’s Q4 FY2025 centers on AI-driven demand, margin stabilization, and the company’s progress in scaling manufacturing operations.TradingKey
5 hours ago
